Plain-English translation of NCT04991948 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment approach for people with advanced colorectal cancer that has spread and cannot be removed with surgery. The trial combines three treatments: (an immune cell therapy), a standard chemotherapy called , and a follow-up immunotherapy drug called . The goal is to see if this combination is safe and whether it can slow or stop the cancer from growing.
Many people with advanced colorectal cancer stop responding to standard treatments. This medication is designed to boost the immune system's ability to recognize and fight cancer cells, and researchers hope combining it with chemotherapy and another immunotherapy will help patients whose cancer has stopped responding to earlier treatments.
You likely qualify if…
You likely don't qualify if…
You would receive the new immune cell treatment () intravenously at the same time as your chemotherapy infusions. After this initial phase, you would then receive as follow-up treatment. Throughout the trial, you would have regular clinic visits for blood tests, scans, and physical exams to monitor how well the treatment is working and check for any side effects. The study is enrolling about 34 patients total.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Belgium